LIVN vs. STVN, GKOS, NARI, IRTC, TMDX, BLCO, INSP, SLNO, PRCT, and NVST
Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Soleno Therapeutics (SLNO), PROCEPT BioRobotics (PRCT), and Envista (NVST). These companies are all part of the "medical equipment" industry.
LivaNova vs. Its Competitors
Stevanato Group (NYSE:STVN) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.
Stevanato Group has a net margin of 10.47% compared to LivaNova's net margin of 1.91%. LivaNova's return on equity of 13.81% beat Stevanato Group's return on equity.
LivaNova received 378 more outperform votes than Stevanato Group when rated by MarketBeat users. Likewise, 69.80% of users gave LivaNova an outperform vote while only 63.27% of users gave Stevanato Group an outperform vote.
Stevanato Group has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.
97.6% of LivaNova shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by company insiders. Comparatively, 0.3% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Stevanato Group has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.
LivaNova has a consensus target price of $59.29, indicating a potential upside of 27.14%. Given LivaNova's stronger consensus rating and higher possible upside, analysts plainly believe LivaNova is more favorable than Stevanato Group.
In the previous week, LivaNova had 2 more articles in the media than Stevanato Group. MarketBeat recorded 4 mentions for LivaNova and 2 mentions for Stevanato Group. LivaNova's average media sentiment score of 0.90 beat Stevanato Group's score of 0.68 indicating that LivaNova is being referred to more favorably in the news media.
Summary
LivaNova beats Stevanato Group on 13 of the 18 factors compared between the two stocks.
Get LivaNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LivaNova Competitors List
Related Companies and Tools
This page (NASDAQ:LIVN) was last updated on 6/13/2025 by MarketBeat.com Staff
